🇺🇸 SECKaryopharm Therapeutics Inc.Doubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:30:05·⟳ 抓取 19:30:30 +25s·⚡ 决策 10-14 19:32:20 +1m50s·12.9 天前
Karyopharm 将债券宽限期例行延长一周至10月22日，无方向性增量
本条是9月10日债务宽限协议的程序性一周展期，既非新增违约/破产，也非解决方案或融资落地，不构成方向性催化；叠加约970万美元市值、0.43美元股价、20日-72%的困境微盘属性与极宽买卖盘，事件驱动交易无edge。
📄 原文Karyopharm Therapeutics Inc.↗ 原文
----- d451522d8k.htm ----- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPOR…
不做 Karyopharm Therapeutics Inc.（KPTI.US）
本条仅为9月10日已披露债务宽限协议的例行一周展期(截止日10/15→10/22)，非新增违约亦非解决方案，无方向性增量；公司处极度财务困境(市值约970万美元、股价0.43美元、20日-72%、5日-34%)，10/22大限前重组/稀释/破产为二元结果，盘前买卖盘极宽、成交极薄，多空均无正期望edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
KPTI 8-K 仅把债券宽限期从10/15例行延至10/22，属程序性展期而非新信息；公司已是濒临违约的极低市值困境股，重组/破产为二元结果且流动性枯竭，不具可交易的方向性edge，故回避。
🔎 新鲜度:最早出现 2026-10-14 · 扩散 low · price-in 风险 medium ↗
关键理由
- 展期本身方向中性：短暂延后强制兑付，却也确认契约困境尚未解决，不提供可交易的正期望。
主要风险
- 10/22前任何重组、稀释性融资、违约或破产消息都会造成股价跳空，属不可对冲的二元事件风险。
- 微盘股盘前买卖盘极宽、成交极薄，滑点与无法成交风险高。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-14 · 影响 weakens
8-K原文未包含任何债务解决、新融资或正面经营进展；股价20日-72%、5日-34%反映持续违约/重组压力，缺乏做多反证支持。
检索:Karyopharm forbearance extension restructuring financing default October 2026 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-10-14 · 影响 invalidates
本条并非新增强空催化(只是展期，短期或带来喘息式反弹)，且微盘股买卖盘极宽、逼空/跳空双向风险大，不满足强空催化门槛，不做空。
检索:KPTI short squeeze forbearance extension deal rebound 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未据此设定任何tp/sl；结论由事件的程序性质与公司流动性/困境状态决定。
方向:无可用对齐先例；且本条为程序性展期而非方向性事件，先例不足以也不需要改变回避结论。
涨幅量级:不足以校准幅度
形态:无可观察的见光死/高开低走样本；实时盘前股价对展期几乎无反应，与‘无增量’判断一致。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`karyopharm forbearance agreement indentures extension october 2026 | karyopharm therapeutics debt forbearance period extended october 22 | kpti forbearance agreement limited waiver`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 956 ms
{ - validate_order 成功 stock_tools HTTP · 7 ms
{
原文全文
展开原文 · 3,006 字
----- d451522d8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 13, 2026
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-36167
26-3931704
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
85 Wells Avenue
,
2nd Floor
Newton
,
Massachusetts
02459
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code:
(617)
658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.0001 par value
KPTI
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.
Other Items.
As previously disclosed in the Current Report on Form
8-K
filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the “Forbearance Agreement”).
On October 13, 2026, in accordance with Section 19 of the Forbearance Agreement, the applicable parties extended the date on which the Forbearance Period (as defined in the Forbearance Agreement) will end, absent earlier termination, from 11:59 p.m., Eastern time, on October 15, 2026 to 11:59 p.m., Eastern time, on October 22, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KARYOPHARM THERAPEUTICS INC.
Date: October 14, 2026
By:
/s/ Michael Mano
Michael Mano
Executive Vice President, Chief Legal Officer and Secretary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 13, 2026
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-36167
26-3931704
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
85 Wells Avenue
,
2nd Floor
Newton
,
Massachusetts
02459
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code:
(617)
658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.0001 par value
KPTI
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.
Other Items.
As previously disclosed in the Current Report on Form
8-K
filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the “Forbearance Agreement”).
On October 13, 2026, in accordance with Section 19 of the Forbearance Agreement, the applicable parties extended the date on which the Forbearance Period (as defined in the Forbearance Agreement) will end, absent earlier termination, from 11:59 p.m., Eastern time, on October 15, 2026 to 11:59 p.m., Eastern time, on October 22, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KARYOPHARM THERAPEUTICS INC.
Date: October 14, 2026
By:
/s/ Michael Mano
Michael Mano
Executive Vice President, Chief Legal Officer and Secretary
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
987b66df24· 2026-10-14 19:32 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前